Egypt condemns Houthi attacks on Saudi territories    NCW files complaint with Public Prosecutor over harassment, rape allegations circulated online    COVID-19 fatalities among Egyptian doctors rise to 116: EMS    Egypt reports 1,324 new COVID-19 cases, 79 fatalities    Egypt says no breakthrough reached on second day of AU-sponsored GERD talks    UAE adopts new government structure, full announcement to come on Sunday    Ministry of Culture announces schedule for resumed theatrical, musical activities    WHO halts hydroxychloroquine, HIV drugs in COVID trials after failure to reduce death    Biggest lenders in Canada join boycott of Facebook platforms    CIAM targets EGP 10bn asset management portfolio year-end    Virtual talks on Ethiopia's disputed dam resume amid consensus hopes    Egypt sees 13.5m mobile wallets end-May: NTRA    Turkish deals with Libya's Sarraj illegal: LNA    Brighton nearly safe after beating last-place Norwich 1-0    Berlin metro to change derogatory station name by end of year    Egypt to hold Senate elections on 11-12 August: NEC    No days off for Liverpool under Klopp: Oxlade-Chamberlain    5 killed, 10 injured in bomb attack in southwest Somalia    Banks in Egypt switch to IBAN standard to ease cross-border transactions    Iran imposes new curbs as coronavirus toll rises    Russia says China would be needed in expanded G7 summit: TASS    Hurghada Airport receives two flights carrying 383 tourists from Ukraine and Belarus    TUI opens bookings to Egypt starting September    Egypt gets its fifth new aircraft from Airbus    Egypt dismisses rumours of imposing tax on bank deposits    Egypt reopens 5 museums, 8 archaeological sites and operates 171 international, domestic flights    Arsenal forward Martinelli signs new long-term deal    Australia's Victoria reports 108 new coronavirus cases, biggest jump since March    $50 bln more required for middle-and low-income Arab countries to recover from COVID-19: ESCWA    GERD talks between Egypt, Ethiopia and Sudan to continue Saturday    GERD talks between Egypt, Ethiopia and Sudan resume on Friday    Rudolfo Anaya, 'godfather' of Chicano literature, dies at 82    Egypt and Jordan's Foreign ministers discuss annexation of West Bank    Lebanon's negotiations with IMF on hold pending start of reforms – minister    Moderna delays coronavirus vaccine trial – report    Egypt developing four WHO-registered vaccines to treat coronavirus patients    Egypt's Zamalek to continue training Thursday, but domestic league participation unclear    Liverpool boss Klopp happy with African Nations Cup postponement    Egypt's cultural activities to resume mid-July    Federation of Egyptian Banks denies funding GERD: eletreby    Saudi development authority starts executing phase I of giant cultural project    Don't miss Al-Hadra troupe's two concerts at El-Sawy Culturewheel    Egypt's President Sisi opens Baron Empain Palace, two int'l airports    11 coronavirus cases detected at Egyptian Premier League clubs – EFA    Egypt to host World Handball Championship on time despite COVID-19: EHF President    Liverpool's Egyptian winger Salah fit for Crystal Palace clash – coach Klopp    Egypt's parliament Oks amendments to House law amid differences over election    CAF draws timeline for resumed continental championships amid COVID-19    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Gilead says remdesivir helped moderate COVID-19 patients improve
Published in Ahram Online on 01 - 06 - 2020

Gilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate COVID-19 in a late-stage study.
Remdesivir is being closely watched after the U.S. Food and Drug Administration granted emergency use authorization last month, citing results from another study run by the National Institutes of Health that showed the drug reduced hospitalization stays by 31%, or about four days, compared to a placebo.
Those results were seen as particularly significant as there are no approved drugs or vaccines for the new coronavirus, although many medicines approved for other conditions, as well as experimental treatments, are being tested to see if they may alter the course of COVID-19, the illness caused by the novel coronavirus.
The new results announced by Gilead on Monday are from a study designed to evaluate the safety and efficacy of 5- and 10-day treatment with remdesivir in addition to standard of care for patients with moderate COVID-19, compared with standard care alone.
At Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, Gilead said.
The drugmaker said the odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance.


Clic here to read the story from its source.